- Home
- Paediatric Neurology
- Efficacy and Safety of Tolebrutinib in Primary Progressive Multiple Sclerosis: Insights from the PERSEUS Phase 3 Trial
3mo3 min read
Medical Article
Introduction: Primary Progressive Multiple Sclerosis (PPMS) is characterised by a gradual accumulation of disability from disease onset, without relapses (1). This form of multiple sclerosis presents significant therapeutic challenges due to the absence of approved disease-modifying therapies (DMTs) (1). The pathophysiology of PPMS involves central

Efficacy and Safety of Tolebrutinib in Primary Progressive Multiple Sclerosis: Insights from the PERSEUS Phase 3 Trial
1000 Reached3 Comments
Similar Content

Young Girl Presented with Irritability and Abnormal Behavior
2254 Reached10 Comments4 Likes

Management of Infantile Myoclonic Seizures
1169 Reached3 Comments3 Likes

Unconscious Male in ED following Loss of Motorcycle Control
828 Reached2 Comments2 Likes

Headache with Clinically Non-functioning Pituitary Adenoma
818 Reached1 Comments4 Likes

OSA in Child
597 Reached3 Comments2 Likes
